Publications by authors named "Xiang-Lan Ma"
Nonmyeloablative allogeneic hematopoietic stem cell transplantation in 26 cases of hematological malignancies.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2006
The purpose of this study was to investigate the efficacy of non-myeloablative allogeneic stem cell transplantation (allo-NST) and its related technologies in hematological malignancies. 26 patients with hematological malignancies (acute leukemia 10, chronic myeloid leukemia 14, multiple myeloma 2) received allo-NST following conditioning regimens with fludarabine/cyclophosphamide/ATG in 14 cases or busulfan or melphalan/cyclophosphamide/ATG in 12 cases prior to infusion of 2 or 3 collections of G-CSF (600 microg/d) or G-CSF (300 microg/d) plus GM-CSF (300 microg/d) mobilized blood stem cell on the fifth day. A combination of cyclosporine A (CsA) and methotrexate (MTX) was administered for GVHD prophylaxis.
View Article and Find Full Text PDF[Non-myeloablative allogeneic stem cell transplantation in patients with hematologic malignancies].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
February 2004
Article Synopsis
- Researchers tested a type of stem cell treatment called non-myeloablative allogeneic stem cell transplantation (allo-NST) on 26 patients with blood cancers.
- Most patients (84.62%) successfully accepted the transplant, and only a few experienced serious side effects like graft-versus-host disease (GVHD).
- The study suggests that allo-NST is a safe and effective way to treat these cancers, but more research is needed on the treatment details.